TriangleNCT02508532 · OUTCOME
Median PFS on Last Prior Anti-cancer Therapy
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Historical data collected at enrollment, all available data on prior therapy was collected
What was measured
Progression Free Survival (PFS) is defined as the time in months from the start of treatment to the date of first documented disease progression or death due to any cause, which ever occurs first. PFS on last prior anti-cancer therapy is defined as the time in months from the start of last prior anti-cancer therapy to progression on that therapy.
Analysis population: Patients enrolled on any dose (Part 1 and Part 2) with data on progression-free survival for the most recent prior therapy
Groups in this outcome
Patients With a PDGFRA D842V Mutation
Patients with a PDGFRA D842V mutation, any line of treatment
2L Patients Without a PDGFRA D842V Mutation
Patients that do not have a PDGFRA D842V mutation and have received 1 prior line of therapy
3L Patients Without a PDGFRA D842V Mutation
Patients that do not have a PDGFRA D842V mutation and have had 2 or more prior lines of therapy
| Group | Source count |
|---|---|
| Patients With a PDGFRA D842V Mutation | 45 |
| 2L Patients Without a PDGFRA D842V Mutation | 51 |
| 3L Patients Without a PDGFRA D842V Mutation | 142 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Patients With a PDGFRA D842V Mutation | 5.9 | Not reported | 4.2 | 8.3 | Not reported |
| 2L Patients Without a PDGFRA D842V Mutation | 31.0 | Not reported | 26.4 | 48.0 | Not reported |
| 3L Patients Without a PDGFRA D842V Mutation | 6.4 | Not reported | 4.3 | 8.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.2
- upper Limit
- 8.3
- value
- 5.9
- group Id
- OG001
- lower Limit
- 26.4
- upper Limit
- 48.0
- value
- 31.0
- group Id
- OG002
- lower Limit
- 4.3
- upper Limit
- 8.3
- value
- 6.4
- denoms
- counts
- group Id
- OG000
- value
- 45
- group Id
- OG001
- value
- 51
- group Id
- OG002
- value
- 142
- units
- Participants
- description
- Progression Free Survival (PFS) is defined as the time in months from the start of treatment to the date of first documented disease progression or death due to any cause, which ever occurs first. PFS on last prior anti-cancer therapy is defined as the time in months from the start of last prior anti-cancer therapy to progression on that therapy.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients with a PDGFRA D842V mutation, any line of treatment
- id
- OG000
- title
- Patients With a PDGFRA D842V Mutation
- description
- Patients that do not have a PDGFRA D842V mutation and have received 1 prior line of therapy
- id
- OG001
- title
- 2L Patients Without a PDGFRA D842V Mutation
- description
- Patients that do not have a PDGFRA D842V mutation and have had 2 or more prior lines of therapy
- id
- OG002
- title
- 3L Patients Without a PDGFRA D842V Mutation
- param Type
- MEDIAN
- population Description
- Patients enrolled on any dose (Part 1 and Part 2) with data on progression-free survival for the most recent prior therapy
- reporting Status
- POSTED
- time Frame
- Historical data collected at enrollment, all available data on prior therapy was collected
- title
- Median PFS on Last Prior Anti-cancer Therapy
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice